2020
DOI: 10.3390/jcm9061790
|View full text |Cite
|
Sign up to set email alerts
|

Biomarkers in Early Diagnosis and Early Stage Lung Cancer: The Clinician’s Point of View

Abstract: Starting from the work of Ulivi and colleagues, we aim to summarize the research area of biomarkers for early diagnosis and early stage lung cancer.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 71 publications
0
3
0
Order By: Relevance
“…Autofluorescence imaging bronchoscopy (AFI) in lung cancer is used in Endobronchial lesions and narrow-band imaging bronchoscopy (NBI) is used to evaluate the diagnosis of premalignant airway lesions in the mucosal and submucosal vascular system [12,13,21]. Low-dose thorax CT (LDCT) screening for early diagnosis of lung cancer for heavy smoking, an increase in diagnosis has been observed [22]. For early-stage non-small cell lung cancer with peripheral blood samples, a concept analysis in 182 patients was evaluated in microRNA when miR-126-3p in disease-free survival and overall survival were statistically significant.…”
Section: Resultsmentioning
confidence: 99%
“…Autofluorescence imaging bronchoscopy (AFI) in lung cancer is used in Endobronchial lesions and narrow-band imaging bronchoscopy (NBI) is used to evaluate the diagnosis of premalignant airway lesions in the mucosal and submucosal vascular system [12,13,21]. Low-dose thorax CT (LDCT) screening for early diagnosis of lung cancer for heavy smoking, an increase in diagnosis has been observed [22]. For early-stage non-small cell lung cancer with peripheral blood samples, a concept analysis in 182 patients was evaluated in microRNA when miR-126-3p in disease-free survival and overall survival were statistically significant.…”
Section: Resultsmentioning
confidence: 99%
“…Despite advances in surgery, radiotherapy, chemotherapy, molecularly targeted therapy, and immunotherapy, the average 5-year survival rate for lung cancer is only 19%. [1][2][3] Several strategies aim to detect lung lesions at an earlier stage: better public awareness of the 'alarm' symptoms of locoregional stage lung cancer (beyond the topic of this review), screening with imaging methods such as chest X-ray or chest CT, screening with biomarkers in blood, lung lavage fluid or exhaled air, and bronchoscopy in individuals at high risk to develop lung cancer. An overview of the most important developments in each of these fields is given.…”
Section: Introductionmentioning
confidence: 99%
“…To our knowledge, even if many biomarkers have been recently reported for early detection and follow-up of chest malignancies [ 31 ], data on FeNO levels and inflammatory cytokines in NSCLC are still few [ 32 ].…”
Section: Introductionmentioning
confidence: 99%